Protemix has identified that the peptide hormone EN122004 may offer a potential treatment for insulin resistance and its associated conditions.

Insulin resistance is an integral feature of Type 2 diabetes, and there is evidence that accumulation of lipid in skeletal muscle is a key metabolic abnormality underlying the development of this condition. Based on Protemix research we have established that EN122004 activates a powerful molecular switch that promotes the effective breakdown of lipid triglycerides in skeletal muscle. Scientific evidence suggests that normalizing muscle lipid improves insulin sensitivity, making EN122004 a potential therapy for managing insulin resistance.

Insulin resistance is a central feature of another common human disorder - Syndrome X. Type 2 diabetes and Syndrome X predispose individuals to cardiovascular disease and serious clinical issues. Treatment of insulin resistance could potentially delay the onset of Type 2 diabetes and reduce cardiovascular complications.